| P2093 | author name string | Dallas P Seitz | |
| | Nathan Herrmann | |
| | Sudeep S Gill | |
| | Mark J Rapoport | |
| | Kimberley Wilson | |
| | David K Conn | |
| | Jenna Rines | |
| | Ken Le Clair | |
| | Sarah Brisbin | |
| P2860 | cites work | Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. | Q51803812 |
| | Nursing home physicians' knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia. | Q51887054 |
| | Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. | Q51898948 |
| | Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. | Q51906702 |
| | Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. | Q51932232 |
| | A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. | Q51981345 |
| | Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. | Q51989663 |
| | Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. | Q51998058 |
| | Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. | Q53285695 |
| | Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. | Q53285762 |
| | A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. | Q53357603 |
| | Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. | Q54002872 |
| | Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia | Q57491167 |
| | Variation in Nursing Home Antipsychotic Prescribing Rates | Q58070500 |
| | A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia | Q61903341 |
| | Mental health service use by the elderly in nursing homes | Q70574622 |
| | Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group | Q73031772 |
| | Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial | Q73082678 |
| | A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia | Q74815220 |
| | Psychiatric consultation in the nursing home. A survey of six states | Q77481222 |
| | The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes | Q79457730 |
| | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia | Q81228549 |
| | Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture | Q82747349 |
| | Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries | Q83688704 |
| | A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) | Q21144654 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| | Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy | Q23791313 |
| | Antidepressants for agitation and psychosis in dementia | Q24236550 |
| | Atypical antipsychotics for aggression and psychosis in Alzheimer's disease | Q24244504 |
| | Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial | Q24555726 |
| | Pharmaceutical industry sponsorship and research outcome and quality: systematic review | Q24673248 |
| | The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary | Q28213792 |
| | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group | Q28371928 |
| | Advances in the treatment of psychiatric disorders in long-term care homes | Q30393588 |
| | Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review | Q30413195 |
| | Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature | Q30540486 |
| | Placebo-controlled study of divalproex sodium for agitation in dementia | Q31825522 |
| | Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials | Q33153605 |
| | Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. | Q33740938 |
| | Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study | Q33869831 |
| | Do atypical antipsychotics cause stroke? | Q33984910 |
| | Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms | Q34025145 |
| | Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients | Q34116373 |
| | Assessment and management of behavioral disturbances in nursing home patients with dementia. | Q34253891 |
| | Atypical antipsychotics and risk of cerebrovascular accidents. | Q34323635 |
| | Risk of death in elderly users of conventional vs. atypical antipsychotic medications | Q34471609 |
| | Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence | Q34554740 |
| | Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. | Q34573456 |
| | Antipsychotic drug use and mortality in older adults with dementia | Q34580030 |
| | Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials | Q34651137 |
| | Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience | Q34661845 |
| | Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study | Q34810990 |
| | Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. | Q34828788 |
| | The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial | Q34920191 |
| | What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home? | Q35685521 |
| | Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. | Q35846062 |
| | Evidence-based interventions for nursing home residents with dementia-related behavioral symptoms | Q36330193 |
| | Pharmacological management of behavioural and psychological disturbance in dementia. | Q36359134 |
| | Neuroleptic drugs in dementia: benefits and harm | Q36484553 |
| | Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients | Q36753193 |
| | Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease | Q37004363 |
| | Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review | Q37019262 |
| | Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease | Q37070699 |
| | Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies | Q37106942 |
| | Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial | Q37271450 |
| | Management of agitation and aggression associated with Alzheimer disease | Q37504709 |
| | Clinical practice guidelines for severe Alzheimer's disease | Q37549302 |
| | Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. | Q37583500 |
| | A metaanalysis of controlled trials of neuroleptic treatment in dementia | Q37586446 |
| | Management of behavioral problems in Alzheimer's disease | Q37680018 |
| | Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review | Q37762607 |
| | Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards | Q39687071 |
| | Psychotropic medications and the risk of fracture: a meta-analysis | Q40248718 |
| | Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease | Q41471899 |
| | Efficacy of antipsychotic medications in behaviorally disturbed dementia patients | Q42264715 |
| | Efficacy and tolerability of carbamazepine for agitation and aggression in dementia | Q42545594 |
| | Risk of ischemic stroke associated with antidepressant drug use in elderly persons | Q43062219 |
| | Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia | Q43657101 |
| | A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease | Q43819464 |
| | A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting | Q43885713 |
| | Behavioral symptoms in residential care/assisted living facilities: prevalence, risk factors, and medication management | Q44169390 |
| | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. | Q44359598 |
| | Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study of 4367 residents | Q44479586 |
| | A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. | Q44488842 |
| | Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia | Q44608310 |
| | Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease | Q44753022 |
| | Paroxetine-induced hyponatremia in older adults: a 12-week prospective study | Q44760337 |
| | The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study | Q44815098 |
| | Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study | Q45079422 |
| | Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia | Q46139039 |
| | A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia | Q46181450 |
| | Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study | Q46375579 |
| | A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease | Q46509399 |
| | Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia | Q46523507 |
| | Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial | Q46623351 |
| | Atypical antipsychotic medications and risk of falls in residents of aged care facilities | Q46633386 |
| | Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS). | Q46729093 |
| | Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial | Q46770122 |
| | Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial | Q46802647 |
| | Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses | Q46920921 |
| | Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial | Q46966417 |
| | Donepezil for the treatment of agitation in Alzheimer's disease | Q46968663 |
| | Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial | Q48448119 |
| | Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study | Q48749105 |
| | Association of cerebrovascular events with antidepressant use: a case-crossover study | Q48891642 |
| | Trends in antipsychotic use in dementia 1999-2007. | Q48915937 |
| | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease | Q48968494 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | pharmacology | Q128406 |
| | antipsychotics | Q208144 |
| | anticonvulsant agent | Q576618 |
| | antidepressant | Q76560 |
| | dementia | Q83030 |
| | systematic review | Q1504425 |
| | mechanism of action | Q3271540 |
| | cholinesterase inhibitors | Q65089169 |
| | psychomotor disease | Q18975697 |
| P304 | page(s) | 185-203 | |
| P577 | publication date | 2012-10-19 | |
| | 2013-02-01 | |
| P1433 | published in | International Psychogeriatrics | Q15761572 |
| P1476 | title | Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review | |
| P478 | volume | 25 | |